RxDoctor Payments Data

Robert Garver

Pulmonary Disease · Andalusia, ALNPI 1639113707

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,465 of the $9,700 with a category attached, or 66.6%. 11 manufacturers reported payments, led by Novartis at 24.5% of the total.

$9,700in general payments, 2019–2025

Across 103 payments — averaging $94.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Astrazeneca UK Limited$2K
  • Eli Lilly$2K
  • Bayer$1K
  • Modernatx, Inc.$1K
  • GSK$240
  • plus $350 from 5 others
$4,562,013in research payments, 2019–2025

Across 585 payments — averaging $7798.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.8M
  • Genentech, Inc.$1.2M
  • AstraZeneca$393K
  • Chiesi USA, Inc.$360K
  • Boehringer Ingelheim$276K
  • Hoffmann-la Roche Limited$250K
  • plus $255K from 8 others

What the payments were for

  • Travel & lodging$6,46567%
  • Food & beverage$3,23533%

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,700 in reported general payments places this provider in the 75th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Other pulmonary disease in Andalusia

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →